



|                    |  |
|--------------------|--|
| <b>Name</b>        | Won Kim  |
| <b>Affiliation</b> | Seoul National University College of Medicine,<br>Seoul Metropolitan Government Boramae Medical Center |
| <b>Country</b>     | Republic of Korea  |
| <b>Major Field</b> | Integrated multi-omics approach for precision medicine in NAFLD  |

### Educational Background

1991-1997 Bachelor's degree, Seoul National University College of Medicine  
2000-2002 Master's degree, Seoul National University College of Medicine  
2005-2007 Doctoral degree, Seoul National University College of Medicine

### Professional Experience

2020-now Associate Professor, Seoul National University College of Medicine  
2018-2019 Director of Research Committee, Korean Liver Cancer Association  
2022-2023 Director of Research and Project Committee, Korean Association for the Study of Liver  
2024-now Director of Publication Committee, Korean Association for the Study of Liver  
2024-now Editor-in-Chief, Clinical and Molecular Hepatology (IF 8.9)  
2023-now President, KASL-Alcohol-Related Problem Study Group

### Main Scientific Publications

1. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. *Journal of Hepatology* (2017)
2. Activating Transcription Factor 3 Is a target molecule linking hepatic steatosis to impaired glucose homeostasis. *Journal of Hepatology* (2017)
3. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. *Journal of Hepatology* (2019)
4. Overproduction of inter--trypsin inhibitor heavy chain 1 after loss of G13 in liver exacerbates systemic insulin resistance in mice. *Science Translational Medicine* (2019)
5. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. *Nature Communication* (2020)
6. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. *Journal of Hepatology* (2021)
7. A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects with Nonalcoholic Fatty Liver Disease. *Clin. Gastroenterol. Hepatol.* (2022)
8. Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis. *Gut Microbes* (2022)
9. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. *Clin. Gastroenterol. Hepatol.* (2023)
10. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. *JAMA Internal Medicine.* (2024)